Nivolumab–Ipilimumab Shows Promising Activity in Gallbladder Cancer: Clinical Cancer Research | August 2026

Introduction:

Dual immune checkpoint blockade with nivolumab plus ipilimumab has shown activity across several malignancies, but its role in advanced biliary tract cancer remains uncertain. The Phase II MoST-CIRCUIT trial evaluated this chemotherapy-free immunotherapy strategy in patients with advanced intrahepatic cholangiocarcinoma (iCCA) and gallbladder cancer (GBC).

Why was this study needed?

PD-1/PD-L1 inhibitors plus chemotherapy are established first-line therapy for advanced biliary tract cancer.

Previous studies suggested potential activity of combined PD-1 and CTLA-4 blockade.

The relative benefit may differ substantially between iCCA and gallbladder cancer.

Better selection of patients for dual immunotherapy is needed.

Results:

Among 60 patients, overall response to nivolumab–ipilimumab was modest at 12%, with median overall survival of 7 months.

Activity differed markedly by tumor type: response was only 3% in iCCA versus 26% in gallbladder cancer.

In immunotherapy-naïve patients, responses were higher, particularly in GBC (38%).

Severe immune-related adverse events occurred in 20% of patients.

Clinical Impact:

The MoST-CIRCUIT trial does not support broad use of nivolumab–ipilimumab across biliary tract cancers, particularly iCCA. However, the substantially higher response observed in gallbladder cancer suggests biologically distinct immunotherapy sensitivity and warrants dedicated prospective trials in this subgroup.

Bottom Line:

Dual nivolumab–ipilimumab showed limited efficacy overall in advanced biliary tract cancer, with minimal activity in intrahepatic cholangiocarcinoma. The notable response signal in gallbladder cancer—especially in immunotherapy-naïve patients—identifies GBC as the subgroup most deserving of further investigation.